Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. operated as a clinical-stage biopharmaceutical company, which was acquired by Sun Pharmaceutical Industries in March 2023. The acquisition was valued at $576 million upfront, with potential for an additional payout to stockholders based on future sales milestones. Founded in April 2006 by scientific founder Roger Tung, Ph.D., who also served as President and CEO, the company focused on applying its proprietary DCE Platform® (deuterated chemical entity platform) to create new small molecule drugs. Tung, a former founding scientist at Vertex Pharmaceuticals, leveraged his extensive experience in drug discovery, where he co-invented and oversaw the development of multiple approved drugs for HIV, hepatitis C, and cystic fibrosis.

The company's core business revolved around modifying known molecules by selectively incorporating deuterium, a non-radioactive isotope of hydrogen. This process aimed to improve a drug's pharmacokinetic or metabolic properties, potentially enhancing its clinical safety, tolerability, or efficacy. The business model focused on identifying previously studied compounds or approved drugs that could be meaningfully improved with this approach, thereby reducing some of the risks and timelines associated with early-stage drug development. This strategy led to collaborations with major pharmaceutical companies, including a 2009 alliance with GlaxoSmithKline to develop deuterium-modified drugs for HIV. The company went public with an IPO in 2014, raising $84 million.

Concert's lead product candidate was deuruxolitinib (formerly CTP-543), an oral inhibitor of Janus kinases (JAK1/2) for the treatment of alopecia areata, a serious autoimmune disease that causes hair loss. This condition affects up to 2.5% of the population and can have significant psychological consequences. Deuruxolitinib successfully completed two Phase 3 clinical trials, THRIVE-AA1 and THRIVE-AA2, demonstrating significant scalp hair regrowth in adults with moderate to severe alopecia areata compared to a placebo. The U.S. FDA had granted the drug Breakthrough Therapy and Fast Track designations. Following the acquisition, Sun Pharma planned to continue Concert's efforts to submit a New Drug Application (NDA) to the FDA, aiming to make deuruxolitinib a best-in-class treatment for this unmet medical need.

Keywords: biopharmaceutical, deuterium chemistry, alopecia areata, JAK inhibitor, clinical-stage, drug development, DCE Platform, autoimmune disease, small molecule drugs, Sun Pharmaceutical